Component‐resolved in vitro diagnosis in carrot allergy: Does the use of recombinant carrot allergens improve the reliability of the diagnostic procedure?
- 6 July 2005
- journal article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 35 (7) , 970-978
- https://doi.org/10.1111/j.1365-2222.2005.02294.x
Abstract
Summary: Background In Europe, pollen‐related food allergy is the most frequent form of food allergy in adults. Reliability of current diagnostic procedures, however, is poor and therapeutic options are not available.Objectives In the present study, we created a panel of recombinant allergens from carrot and evaluated its potential in component‐resolved in vitro diagnosis of carrot allergy.Methods Recombinant (r) Dau c 1.0104, Dau c 1.0201 and Dau c 4 were cloned by a polymerase chain reaction strategy, expressed in Escherichia coli and purified. Carrot lipid transfer protein (LTP) was expressed in the yeast Pichia pastoris. Sera from 40 carrot‐allergic patients were investigated. Twenty‐one birch pollen‐allergic subjects with negative open provocation to carrot and 20 non‐allergic subjects were included as controls. IgE binding to recombinant allergens as well as to cross‐reactive carbohydrate determinants (CCD) was measured by ELISA. Cross‐reactivity between Dau c 1 isoforms and Bet v 1 was assayed by ELISA inhibition.Biological activity of the recombinant carrot allergens was assessed by histamine release assay and peripheral blood mononuclear cells stimulation.Results Ninety‐eight percent of the carrot‐allergic patients were positive to at least one recombinant allergen; 98% reacted to rDau c 1.0104, 65% to rDau c 1.0201, 38% to rDau c 4 and 20% had IgE against CCD. Specificity using the recombinant allergens was high when compared with non‐allergic controls, but low compared with birch‐sensitized subjects without carrot allergy. Sensitization to Dau c 1.0201, however, proved to be highly specific for clinically relevant sensitization. Inhibition assays indicated the absence of LTP in carrot root extract, and epitope diversity between Dau c 1.0104, Dau c 1.0201 and Bet v 1.Conclusions Our panel of recombinant allergens from carrot can provide a standardized tool for in vitro diagnosis of carrot allergy, and for epitope studies.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy of birch‐pollen immunotherapy on cross‐reactive food allergy confirmed by skin tests and double‐blind food challengesClinical and Experimental Allergy, 2004
- Soybean allergy in patients allergic to birch pollen☆Clinical investigation and molecular characterization of allergensJournal of Allergy and Clinical Immunology, 2004
- Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell levelEuropean Journal of Immunology, 2003
- Carrot allergy: Double-blinded, placebo-controlled food challenge and identification of allergensJournal of Allergy and Clinical Immunology, 2001
- Molecular characterization of Dau c 1, the Bet v 1 homologous protein from carrot and its cross‐reactivity with Bet v 1 and Api g 1Clinical and Experimental Allergy, 1999
- Characterization of the 18-kDa Apple Allergen by Two-Dimensional Immunoblotting and MicrosequencingInternational Archives of Allergy and Immunology, 1994
- Cell-specific expression of the carrot EP2 lipid transfer protein gene.Plant Cell, 1991
- Peptide‐N4‐(N‐acetyl‐β‐glucosaminyl)asparagine amidase F cannot release glycans with fucose attached α1 → 3 to the asparagine‐linked N‐acetylglucosamine residueEuropean Journal of Biochemistry, 1991
- Allergy to Apple, Carrot and Potato in Children with Birch Pollen AllergyAllergy, 1983